NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17
NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dex Versus Lenalidomide and Dex High- Risk SMM
Phase II HOVON 143 Study: Ixazomib, Dara and Low Dose Dex in Intermediate-Fit Patients NDMM
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
NCT01208766: Phase 3 - EMN02 - Compare VMP With HDM f/b VRD Consol & Lenalidomide Maint. NDMM (HO95)
Bortezomib before & after high-dose therapy in myeloma: phase III HOVON-65/GMMG-HD4 trial